If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
EMGALITY® (galcanezumab-gnlm): Metabolism and Elimination
Emgality (galcanezumab) is expected to be degraded via catabolic pathways in the same manner as endogenous IgG.
Additional Information Regarding Metabolism and Elimination
Galcanezumab is an IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1,2
As such, it is not expected to
-
inhibit metabolic or induce enzymatic pathways
-
be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
The CL/F was 0.008 L/h and the elimination half-life of galcanezumab was approximately 27 days.1,2
Enclosed Prescribing Information
EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
2. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
4. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178
Glossary
CL/F = apparent clearance
IgG = immunoglobulin G
IgG4 = immunoglobulin G (subclass) 4
Date of Last Review: July 22, 2020